Regulatory Filings • May 5, 2015
Regulatory Filings
Open in ViewerOpens in native device viewer
PRESS RELEASE
May 4, 2015 – Paris (France) – Cellectis S.A. (Alternext: ALCLS – Nasdaq Global Market: CLLS) a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that it has changed the name of its subsidiary, Cellectis plant sciences, Inc. to Calyxt, Inc.
The name change is part of Cellectis' effort to further distinguish the parent company's focus from that of it subsidiary. Gene editing is the common base of the two companies: it is used by Cellectis in the development of new and innovative product candidates for treatment of cancers, and by Calyxt in the development of improved crops for consumers with healthier characteristics.
The goal of the name change is to leverage the strengths of both Cellectis and Calyxt brand identities.
To find out more about Calyxt, please visit www.calyxt.com
Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genomeengineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Jennifer Moore, Director of Communications Phone: 917-580-1088 email: [email protected]
Brad Miles Phone: 646-513-3125 email: [email protected]
IR contacts Simon Harnest, VP Finance and Investor Relations Phone: 646-385-9008 email: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.